Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2009 - 2026)

Ionis Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $75.7 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 46.16% year-over-year to $75.7 million; the TTM figure through Mar 2026 stood at $75.7 million (down 46.16% YoY), while the FY2025 annual figure was $92.0 million, down 41.21% from the prior year.
• Non-Current Deffered Revenue was $75.7 million for Q1 2026 at Ionis Pharmaceuticals, down from $92.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $333.1 million in Q1 2022 to a low of $75.7 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $207.3 million across 5 years, with a median of $215.1 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue slipped 15.4% in 2023, then slumped 46.16% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $287.8 million in 2022, then fell by 16.19% to $241.2 million in 2023, then sank by 35.11% to $156.5 million in 2024, then slumped by 41.21% to $92.0 million in 2025, then dropped by 17.67% to $75.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $75.7 million (Q1 2026), $92.0 million (Q4 2025), and $107.9 million (Q3 2025), per Business Quant data.